Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.36 |
| ▸ | SLC2A3 | P11169 | 2/20 | 0.36 |
| ▸ | SLC2A4 | P14672 | 2/20 | 0.36 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.36 |
| ▸ | PDE8B | O95263 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | PDE1A | P54750 | 1/20 | 0.34 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.34 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.34 |
| ▸ | CCR1 | P32246 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19702817 | 0.85 | CYP1A2 (0.41) | NPBWR1SMN1; SMN2PDE8BCNR1CNR2 | |
| SCHEMBL17777911 | 0.82 | NPBWR1 (0.38) | NPBWR1PDE8BGRIN1GRIN2BCNR1 | |
| SCHEMBL17777906 | 0.81 | MET (0.41) | SMN1; SMN2GAA | |
| SCHEMBL17777767 | 0.80 | KDM4E (0.38) | NPBWR1PDE8BCNR1CNR2 | |
| SCHEMBL13748686 | 0.76 | NPBWR1 (0.42) | NPBWR1SMN1; SMN2SLC2A1SLC2A3SLC2A4 | |
| SCHEMBL17777970 | 0.74 | MET (0.41) | SMN1; SMN2GAAGRIN1GRIN2B | |
| SCHEMBL19659814 | 0.72 | KDM4E (0.38) | SMN1; SMN2PDE8BGAACNR2PDE1A | |
| SCHEMBL13755154 | 0.71 | NPBWR1 (0.44) | NPBWR1SMN1; SMN2SLC2A1SLC2A3SLC2A4 | |
| SCHEMBL15348694 | 0.70 | CNR1 (0.46) | NPBWR1SMN1; SMN2GRIN1GRIN2BCNR1 | |
| SCHEMBL22912862 | 0.70 | CNR1 (0.43) | NPBWR1SMN1; SMN2SLC2A1SLC2A3GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183247-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | AKARNA THERAPEUTICS LTD (GB) | 2023-06-15 | — | — | US | disclosed |
| EP-3221321-B1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | AKARNA THERAPEUTICS LTD (GB) | 2021-12-15 | — | — | EP | disclosed |
| EP-3715348-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | Akarna Therapeutics, Ltd. (GB) | 2020-09-30 | — | — | EP | disclosed |
| WO-2017205684-A1 | COMBINATION THERAPIES WITH FARNESOID X RECEPTOR (FXR) MODULATORS | AKARNA THERAPEUTICS, LTD. (GB) | 2017-11-30 | — | — | WO | disclosed |
| WO-2016151403-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | AKARNA THERAPEUTICS, LTD. (GB) | 2016-09-29 | — | — | WO | disclosed |
| WO-2016081918-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | AKARNA THERAPEUTICS, LTD. (GB) | 2016-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183247-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | VHL, BRDT, PAICS | NPBWR1 4315/4885SMN1; SMN2 61/4885SLC2A1 3788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.